Evidence map›Paper›PMID 37827154›Full record

ArticleCell reports. Medicine2023

Genetic and pharmaceutical targeting of HIF1α allows combo-immunotherapy to boost graft vs. leukemia without exacerbation graft vs. host disease.

Christopher Bailey, Yuanyi Wei, Jinsong Yan, Dan Huang, Peng Zhang, Chong Qi, Christopher Lazarski, JuanJuan Su, Fei Tang, Chun-Shu Wong and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Christopher BaileyDivision of Immunotherapy, Institute of Human Virology, Department of Surgery and Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Yuanyi WeiDivision of Immunotherapy, Institute of Human Virology, Department of Surgery and Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Jinsong YanDepartment of Hematology, The Second Hospital of Dalian Medical University, Dalian, China.
Dan HuangDepartment of Hematology, The Second Hospital of Dalian Medical University, Dalian, China.
Peng ZhangDepartment of Neurosurgery, Beijing Children's Hospital, Capital Medical University, National Cancer for Children's Health, Beijing, China.
Chong QiInstitute of Translational Medicine, The First Hospital, Jilin University, Changchun, Jilin 130061, China.
Christopher LazarskiCenter for Cancer and Immunology Research, Children's Research Institute, Washington, DC 20010, USA.
JuanJuan SuDivision of Immunotherapy, Institute of Human Virology, Department of Surgery and Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Fei TangDivision of Immunotherapy, Institute of Human Virology, Department of Surgery and Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Chun-Shu WongCenter for Cancer and Immunology Research, Children's Research Institute, Washington, DC 20010, USA.
Pan ZhengDivision of Immunotherapy, Institute of Human Virology, Department of Surgery and Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; OncoC4, Inc., Rockville, MD 20852, USA.
Yan LiuDivision of Immunotherapy, Institute of Human Virology, Department of Surgery and Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Electronic address: yanliu@ihv.umaryland.edu.
Yang LiuDivision of Immunotherapy, Institute of Human Virology, Department of Surgery and Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA; OncoC4, Inc., Rockville, MD 20852, USA. Electronic address: yangl@oncoc4.com.
Yin WangDivision of Immunotherapy, Institute of Human Virology, Department of Surgery and Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Electronic address: yin.wang@ihv.umaryland.edu.
University of Maryland, Baltimore · USCenter for Cancer and Blood Disorders · USDalian Medical University · CNCapital Medical University · CNJilin University · CN

Funding

Targeted Elimination of Cancer Stem Cells for AML TherapyR01CA171972 · NCI · CHILDREN'S RESEARCH INSTITUTE · PI LIU, YANG, MALEK, SAMI NIMER · 2013 to 2017
$2.3M
Therapeutic Elimination of Stem Cells for Relapsed Pediatric AMLU01CA183030 · NCI · CHILDREN'S RESEARCH INSTITUTE · PI LIU, YANG, SCHORE, REUVEN J · 2014 to 2017
$2.3M
A Mouse Model to Assess Long Term Immunotherapy-related Adverse Effects in ChildrenR01CA227671 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WANG, YIN · 2018 to 2022
$2.1M
Anticancer peptide therapeuticsR01CA219150 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI WANG, YIN · 2017 to 2022
$1.7M
NCI NIH HHS R01 CA171972NCI NIH HHS R01 CA219150NCI NIH HHS R01 CA227671NCI NIH HHS U01 CA183030
6 · The paper itself

Abstract

Despite potential impact on the graft vs. leukemia (GVL) effect, immunotherapy targeting CTLA-4 and/or PD-1 has not been successfully combined with bone marrow transplant (BMT) because it exacerbates graft vs. host disease (GVHD). Here, using models of GVHD and leukemia, we demonstrate that targeting hypoxia-inducible factor 1α (HIF1α) via pharmacological or genetic approaches reduces GVHD by inducing PDL1 expression on host tissue while selectively inhibiting PDL1 in leukemia cells to enhance the GVL effect. More importantly, combination of HIF1α inhibition with anti-CTLA-4 antibodies allows simultaneous inhibition of both PDL1 and CTLA-4 checkpoints to achieve better outcomes in models of mouse and human BMT-leukemia settings. These findings provide an approach to enhance the curative effect of BMT for leukemia and broaden the impact of cancer immunotherapy.

Indexed as

Graft vs Host DiseaseLeukemiaAnimalsCTLA-4 AntigenHumansHypoxia-Inducible Factor 1, alpha SubunitImmunotherapyMiceCTLA-4 AntigenHypoxia-Inducible Factor 1, alpha Subunitbone marrow transplantationcytotoxic T-lymphocyte associated protein 4graft vs. host diseasegraft vs. leukemiahypoxia-inducible factor 1αimmune checkpoint inhibitorimmunotherapy-related adverse eventsprogrammed Cell Death 1programmed death ligand 1

Identifiers

PMID37827154
PMCPMC10694596
OpenAlexW4387540785

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.